# A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function

> **NCT02372084** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 33 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** osilodrostat

## Key facts

- **NCT ID:** NCT02372084
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-21
- **Primary completion:** 2016-05-19
- **Final completion:** 2016-05-19
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02372084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02372084, "A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02372084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*